NAMS — NewAmsterdam Pharma Share News
0.000.00%
Last trade - 00:00- $2.46bn
- $1.83bn
- $22.50m
Amgen falls after Novartis trial setback, BMO downgrade
Brief: Newamsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Newamsterdam Pharma Company N.V. - Announces Positive CHMP Opinion For Obicetrapib And Obicetrapib/Ezetimibe
Brief: NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Newamsterdam Pharma Highlights 2025 Achievements And Outlines 2026 Strategic Priorities
Brief: Newamsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Newamsterdam Pharma Announces Positive Alzheimer’S Disease Data From Broadway Clinical Trial
Brief: Newamsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: NewAmsterdam Pharma Company NV Files For Mixed Shelf Of Up To $500 Million - SEC Filing
Brief: Newamsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: NewAmsterdam Pharma Highlights 2024 Achievements And Outlines 2025 Strategic Priorities
Brief: Newamsterdam Pharma Announces Pricing Of 12.1 Mln Of Ordinary Shares At $24.50 Per Share
US-listed shares of NewAmsterdam Pharma fall on planned $300 mln public offering
Brief: Newamsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
U.S. RESEARCH ROUNDUP-Microstrategy, Snowflake, Target
Brief: NewAmsterdam Pharma Announces Positive Topline Data From Pivotal Phase 3 Tandem Clinical Trial
Brief: Newamsterdam Pharma To Announce Topline Data From Pivotal Phase 3 Brooklyn Clinical Trial On Monday
Brief: NeNewAmsterdam Pharma Completes Enrollment in Pivotal Phase 3 TANDEM Clinical Trial Evaluating Fixed-Dose Combination of Obicetrapib plus Ezetimibe in Patients with HeFH and/or ASCVD or ASCVD Risk Factors
Brief: Newamsterdam Pharma Company NV Issuance Of Composition Of Matter Patent For Obicetrapib By United States Patent And Trademark Office